Want to see NL:LKFT full AI Analyst Report?
LKFT Stock Chart & Stats
€24.70
-€0.26(-1.07%)
At close: 4:00 PM EST
€24.70
-€0.26(-1.07%)
Day’s Range― - ―
52-Week Range€22.62 - €32.74
Previous CloseN/A
VolumeN/A
Average Volume (3M)132.01K
Market Cap
€1.76B
Enterprise Value€1.52B
Total Cash (Recent Filing)€2.98B
Total Debt (Recent Filing)€6.43M
Price to Earnings (P/E)3.6
Beta0.72
Next Earnings
Aug 10, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.39
Shares Outstanding65,897,070
10 Day Avg. Volume76,560
30 Day Avg. Volume132,014
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.75Price Target Upside-7.89% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-2.8
Revenue Forecast (FY)€24.34M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a large equity base give durable financial flexibility for a capital‑intensive biotech. This reduces insolvency and refinancing risk, allowing multi‑period funding of R&D and clinical programs without immediate reliance on markets or partners.
High And Sustainable MarginsVery high gross and operating margins indicate strong pricing power or favorable revenue mix, which supports long‑term profitability even if top‑line fluctuates. Durable margins improve cash retention potential and the ability to fund strategic programs once cash flow turns.
Improving Returns On CapitalROE improvement to ~16% shows management is generating stronger returns from its equity base. Combined with the large equity cushion, this creates a durable capacity to invest in growth initiatives and absorb near‑term losses without immediate capital raises.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business is not self‑funding and must draw on equity or financing to continue operations. Over months this raises dilution or financing risk and constrains the firm's ability to scale without tapping its balance sheet.
Revenue Volatility And Recent DeclineTop‑line instability—declining revenue following a prior step‑up—reduces predictability for R&D spend and operating planning. Over a 2–6 month horizon, uneven revenue trends complicate resource allocation and increase the chance that margins or investment plans will be adjusted.
Historic Earnings VolatilityA track record of earnings swings implies current profitability may be unstable. For a biotech, binary outcomes and uneven commercial uptake can reverse earnings quickly, making current margin and ROE improvements less certain as durable indicators of future performance.
Galapagos News
LKFT FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest stock price was €22.62 and its highest was €32.74 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is €1.76B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is Aug 10, 2026 which is in 30 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on May 06, 2026. The company reported €0.21 earnings per share for the quarter, beating the consensus estimate of -€0.815 by €1.025.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Overvalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.7.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of €0.21 in its last earnings report, beating expectations of -€0.815. Following the earnings report the stock price went down -4.224%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in NL:LKFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
LKFT Stock 12 Month Forecast
Average Price Target
€22.75
▼(-7.89% Downside)
Technical Analysis
Options Prices
Currently, No data available
---